|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5F1E |
Gene summary for ATP5F1E |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5F1E | Gene ID | 514 |
| Gene name | ATP synthase F1 subunit epsilon | |
| Gene Alias | ATP5E | |
| Cytomap | 20q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P56381 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 514 | ATP5F1E | GSM4909281 | Human | Breast | IDC | 2.59e-20 | 3.75e-01 | 0.21 |
| 514 | ATP5F1E | GSM4909282 | Human | Breast | IDC | 6.02e-23 | 5.15e-01 | -0.0288 |
| 514 | ATP5F1E | GSM4909285 | Human | Breast | IDC | 5.53e-35 | 2.69e-01 | 0.21 |
| 514 | ATP5F1E | GSM4909286 | Human | Breast | IDC | 5.99e-32 | 5.51e-01 | 0.1081 |
| 514 | ATP5F1E | GSM4909287 | Human | Breast | IDC | 2.39e-31 | 5.99e-01 | 0.2057 |
| 514 | ATP5F1E | GSM4909289 | Human | Breast | IDC | 1.97e-07 | 5.66e-01 | 0.1064 |
| 514 | ATP5F1E | GSM4909290 | Human | Breast | IDC | 1.59e-31 | 6.51e-01 | 0.2096 |
| 514 | ATP5F1E | GSM4909291 | Human | Breast | IDC | 6.17e-30 | 6.76e-01 | 0.1753 |
| 514 | ATP5F1E | GSM4909293 | Human | Breast | IDC | 7.20e-55 | 7.54e-01 | 0.1581 |
| 514 | ATP5F1E | GSM4909294 | Human | Breast | IDC | 9.29e-35 | 7.31e-01 | 0.2022 |
| 514 | ATP5F1E | GSM4909295 | Human | Breast | IDC | 3.16e-09 | 4.75e-01 | 0.0898 |
| 514 | ATP5F1E | GSM4909296 | Human | Breast | IDC | 1.30e-27 | 6.74e-01 | 0.1524 |
| 514 | ATP5F1E | GSM4909297 | Human | Breast | IDC | 5.82e-32 | 6.23e-01 | 0.1517 |
| 514 | ATP5F1E | GSM4909298 | Human | Breast | IDC | 5.11e-49 | 7.58e-01 | 0.1551 |
| 514 | ATP5F1E | GSM4909299 | Human | Breast | IDC | 5.87e-25 | 5.76e-01 | 0.035 |
| 514 | ATP5F1E | GSM4909300 | Human | Breast | IDC | 1.43e-13 | 5.15e-01 | 0.0334 |
| 514 | ATP5F1E | GSM4909301 | Human | Breast | IDC | 4.92e-108 | 9.88e-01 | 0.1577 |
| 514 | ATP5F1E | GSM4909302 | Human | Breast | IDC | 3.46e-20 | 5.01e-01 | 0.1545 |
| 514 | ATP5F1E | GSM4909303 | Human | Breast | IDC | 1.44e-14 | 6.74e-01 | 0.0438 |
| 514 | ATP5F1E | GSM4909304 | Human | Breast | IDC | 9.25e-81 | 8.84e-01 | 0.1636 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000926017 | Oral cavity | OSCC | ribonucleotide biosynthetic process | 88/7305 | 182/18723 | 6.29e-03 | 2.35e-02 | 88 |
| GO:004603426 | Oral cavity | EOLP | ATP metabolic process | 68/2218 | 277/18723 | 2.72e-09 | 1.71e-07 | 68 |
| GO:000611925 | Oral cavity | EOLP | oxidative phosphorylation | 33/2218 | 141/18723 | 8.63e-05 | 1.02e-03 | 33 |
| GO:000906025 | Oral cavity | EOLP | aerobic respiration | 40/2218 | 189/18723 | 1.76e-04 | 1.81e-03 | 40 |
| GO:004533325 | Oral cavity | EOLP | cellular respiration | 44/2218 | 230/18723 | 8.67e-04 | 6.75e-03 | 44 |
| GO:000683925 | Oral cavity | EOLP | mitochondrial transport | 46/2218 | 254/18723 | 2.16e-03 | 1.35e-02 | 46 |
| GO:000609125 | Oral cavity | EOLP | generation of precursor metabolites and energy | 79/2218 | 490/18723 | 2.65e-03 | 1.59e-02 | 79 |
| GO:001598025 | Oral cavity | EOLP | energy derivation by oxidation of organic compounds | 54/2218 | 318/18723 | 4.02e-03 | 2.23e-02 | 54 |
| GO:004603433 | Oral cavity | NEOLP | ATP metabolic process | 71/2005 | 277/18723 | 1.44e-12 | 3.17e-10 | 71 |
| GO:000611932 | Oral cavity | NEOLP | oxidative phosphorylation | 40/2005 | 141/18723 | 4.88e-09 | 2.74e-07 | 40 |
| GO:000906032 | Oral cavity | NEOLP | aerobic respiration | 45/2005 | 189/18723 | 1.84e-07 | 6.26e-06 | 45 |
| GO:004533332 | Oral cavity | NEOLP | cellular respiration | 49/2005 | 230/18723 | 1.85e-06 | 4.45e-05 | 49 |
| GO:001598033 | Oral cavity | NEOLP | energy derivation by oxidation of organic compounds | 59/2005 | 318/18723 | 1.78e-05 | 3.01e-04 | 59 |
| GO:000609133 | Oral cavity | NEOLP | generation of precursor metabolites and energy | 82/2005 | 490/18723 | 2.70e-05 | 4.22e-04 | 82 |
| GO:000915025 | Oral cavity | NEOLP | purine ribonucleotide metabolic process | 55/2005 | 368/18723 | 6.80e-03 | 3.46e-02 | 55 |
| GO:000925925 | Oral cavity | NEOLP | ribonucleotide metabolic process | 57/2005 | 385/18723 | 7.23e-03 | 3.66e-02 | 57 |
| GO:001969325 | Oral cavity | NEOLP | ribose phosphate metabolic process | 58/2005 | 396/18723 | 8.46e-03 | 4.13e-02 | 58 |
| GO:004603418 | Prostate | BPH | ATP metabolic process | 120/3107 | 277/18723 | 4.78e-26 | 1.48e-22 | 120 |
| GO:000611917 | Prostate | BPH | oxidative phosphorylation | 77/3107 | 141/18723 | 5.53e-25 | 1.14e-21 | 77 |
| GO:000906016 | Prostate | BPH | aerobic respiration | 86/3107 | 189/18723 | 9.81e-21 | 1.01e-17 | 86 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 514 | ATP5F1E | TRANSPORTER | glucocorticoids | 26307125 | ||
| 514 | ATP5F1E | TRANSPORTER | etanercept | ETANERCEPT | 26307125 | |
| 514 | ATP5F1E | TRANSPORTER | adalimumab | ADALIMUMAB | 26307125 | |
| 514 | ATP5F1E | TRANSPORTER | certolizumab pegol | 26307125 | ||
| 514 | ATP5F1E | TRANSPORTER | methotrexate | METHOTREXATE | 26307125 | |
| 514 | ATP5F1E | TRANSPORTER | infliximab | INFLIXIMAB | 26307125 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |